Comparison between patients with normal and pathological findings at predischarge testing (PDT)
| Normal PDT | Pathological PDT | p-Value | |
| Patients (n) | 144 | 17 | |
| Clinical variables | |||
| Mean age (years) | 64 ± 11 | 61 ± 13 | n.s. |
| Men/women | 113/31 (78%/22%) | 14/3 (82%/18%) | n.s. |
| CHD | 101 (78%) | 11 (65%) | n.s. |
| LVEF | 0.41 ± 0.14 | 0.41 ± 0.18 | n.s. |
| Amiodarone therapy | 78 (54%) | 11 (65%) | n.s. |
| Single chamber device | 113 (78%) | 12 (71%) | n.s. |
| PDT delay (days) | 6 ± 2 | 7 ± 1 | <0.001 |
| Measurements during implantation | |||
| R-wave sensing (mV) | 13.4 ± 5.0 | 13.1 ± 4.7 | n.s. |
| Pacing threshold ([email protected] ms) | 0.6 ± 0.2 | 0.7 ± 0.4 | n.s. |
| HV lead impedance (Ω) | 42 ± 11 | 42 ± 6 | n.s. |
| Normal PDT | Pathological PDT | p-Value | |
| Patients (n) | 144 | 17 | |
| Clinical variables | |||
| Mean age (years) | 64 ± 11 | 61 ± 13 | n.s. |
| Men/women | 113/31 (78%/22%) | 14/3 (82%/18%) | n.s. |
| CHD | 101 (78%) | 11 (65%) | n.s. |
| LVEF | 0.41 ± 0.14 | 0.41 ± 0.18 | n.s. |
| Amiodarone therapy | 78 (54%) | 11 (65%) | n.s. |
| Single chamber device | 113 (78%) | 12 (71%) | n.s. |
| PDT delay (days) | 6 ± 2 | 7 ± 1 | <0.001 |
| Measurements during implantation | |||
| R-wave sensing (mV) | 13.4 ± 5.0 | 13.1 ± 4.7 | n.s. |
| Pacing threshold ([email protected] ms) | 0.6 ± 0.2 | 0.7 ± 0.4 | n.s. |
| HV lead impedance (Ω) | 42 ± 11 | 42 ± 6 | n.s. |
CHD = coronary heart disease, LVEF = left ventricular ejection fraction, HV = high voltage.
Comparison between patients with normal and pathological findings at predischarge testing (PDT)
| Normal PDT | Pathological PDT | p-Value | |
| Patients (n) | 144 | 17 | |
| Clinical variables | |||
| Mean age (years) | 64 ± 11 | 61 ± 13 | n.s. |
| Men/women | 113/31 (78%/22%) | 14/3 (82%/18%) | n.s. |
| CHD | 101 (78%) | 11 (65%) | n.s. |
| LVEF | 0.41 ± 0.14 | 0.41 ± 0.18 | n.s. |
| Amiodarone therapy | 78 (54%) | 11 (65%) | n.s. |
| Single chamber device | 113 (78%) | 12 (71%) | n.s. |
| PDT delay (days) | 6 ± 2 | 7 ± 1 | <0.001 |
| Measurements during implantation | |||
| R-wave sensing (mV) | 13.4 ± 5.0 | 13.1 ± 4.7 | n.s. |
| Pacing threshold ([email protected] ms) | 0.6 ± 0.2 | 0.7 ± 0.4 | n.s. |
| HV lead impedance (Ω) | 42 ± 11 | 42 ± 6 | n.s. |
| Normal PDT | Pathological PDT | p-Value | |
| Patients (n) | 144 | 17 | |
| Clinical variables | |||
| Mean age (years) | 64 ± 11 | 61 ± 13 | n.s. |
| Men/women | 113/31 (78%/22%) | 14/3 (82%/18%) | n.s. |
| CHD | 101 (78%) | 11 (65%) | n.s. |
| LVEF | 0.41 ± 0.14 | 0.41 ± 0.18 | n.s. |
| Amiodarone therapy | 78 (54%) | 11 (65%) | n.s. |
| Single chamber device | 113 (78%) | 12 (71%) | n.s. |
| PDT delay (days) | 6 ± 2 | 7 ± 1 | <0.001 |
| Measurements during implantation | |||
| R-wave sensing (mV) | 13.4 ± 5.0 | 13.1 ± 4.7 | n.s. |
| Pacing threshold ([email protected] ms) | 0.6 ± 0.2 | 0.7 ± 0.4 | n.s. |
| HV lead impedance (Ω) | 42 ± 11 | 42 ± 6 | n.s. |
CHD = coronary heart disease, LVEF = left ventricular ejection fraction, HV = high voltage.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
